共 27 条
[11]
Bibikova M(2000)Single-nucleotide polymorphism analysis by MALDI-TOF mass spectrometry Trends In Biotechnology 18 77-84
[12]
Wang RY(2009)& Clifford, S.C. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials British Journal Of Neurosurgery 23 364-375
[13]
Gehrke CW(2013)DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies Acta Neuropathologica 125 359-371
[14]
Ehrlich M(2013)Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays Acta Neuropathologica 125 913-916
[15]
Griffin TJ(2012)Molecular subgroups of medulloblastoma: the current consensus Acta Neuropathologica 123 465-472
[16]
Smith LM(2012)Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial Journal of Clinical Oncology 30 3187-3193
[17]
Pizer BL(2015)Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial Oncotarget 6 38827-38839
[18]
Schwalbe EC(2004)Metagenes and molecular pattern discovery using matrix factorization Proceedings of the National Academy of Sciences of the United States of America 101 4164-4169
[19]
Hovestadt V(2015)Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease Cancer Cell 27 72-84
[20]
Taylor MD(undefined)undefined undefined undefined undefined-undefined